Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216515
Status:
COMPLETED
Last Update Posted:
2011-01-24
First Post:
2005-09-13
Brief Title:
The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
Sponsor:
Janssen Korea Ltd Korea
Organization:
Janssen Korea Ltd Korea
Study Overview
Official Title:
A Prospective Open-labeled Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimers Disease how an improvement of attention of Alzheimers Disease patients affects their activities of daily living and the global benefit of galantamine
Detailed Description:
Recent studies suggest that an attention deficit occurs at early stage of Alzheimers disease and affects patients activities of daily living In other words some patients without language or visuospatial dysfunction have severe impairment of activities of daily living which might result from attention deficit Another recent clinical study showed that galantamine is more effective in attention and vigilance of Alzheimers disease patients than donepezil The study hypothesis is that galantamine will improve attention and frontal executive function in Alzheimers disease patients and is well-tolerated 8 mgday for the first 4 weeks 16 mg for the next 8 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None